ES2040847T3 - Un procedimiento para preparar una composicion farmaceutica que contiene una sal de litio. - Google Patents

Un procedimiento para preparar una composicion farmaceutica que contiene una sal de litio.

Info

Publication number
ES2040847T3
ES2040847T3 ES88303560T ES88303560T ES2040847T3 ES 2040847 T3 ES2040847 T3 ES 2040847T3 ES 88303560 T ES88303560 T ES 88303560T ES 88303560 T ES88303560 T ES 88303560T ES 2040847 T3 ES2040847 T3 ES 2040847T3
Authority
ES
Spain
Prior art keywords
preparing
procedure
pharmaceutical composition
composition containing
lithium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88303560T
Other languages
English (en)
Inventor
David Frederick Horrobin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Efamol Holdings PLC
Original Assignee
Efamol Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878709892A external-priority patent/GB8709892D0/en
Priority claimed from GB878719988A external-priority patent/GB8719988D0/en
Application filed by Efamol Holdings PLC filed Critical Efamol Holdings PLC
Application granted granted Critical
Publication of ES2040847T3 publication Critical patent/ES2040847T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/06—Unsaturated carboxylic acids or thio analogues thereof; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)

Abstract

LA INVENCION PROPORCIONA COMPOSICIONES FARMACEUTICAS Y DESINFECTANTES QUE CONTIENEN SALES DE LITIO DE ACIDOS GRASOS POLIINSATURADOS DE 18 A 22 C. LAS COMPOSICIONES SE PUEDEN EMPLEARPARA EL TRATAMIENTO DE CONDICIONES QUE RESPONDEN A TERAPIA CON LITIO O CON ACIDOS GRASOS POLIINSATURADOS, EN ALIMENTACION PARENTERAL, COMO SUPLEMENTOALIMENTICIO O EN DESINFECCION SUPERFICIAL PARA COMBATIR LA TRANSMISION DE ENFERMEDADES VIRICAS
ES88303560T 1987-04-27 1988-04-20 Un procedimiento para preparar una composicion farmaceutica que contiene una sal de litio. Expired - Lifetime ES2040847T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB878709892A GB8709892D0 (en) 1987-04-27 1987-04-27 Virucidal compositions
GB878719988A GB8719988D0 (en) 1987-08-25 1987-08-25 Chemical compounds
GB888802016A GB8802016D0 (en) 1987-04-27 1988-01-29 Chemical compositions

Publications (1)

Publication Number Publication Date
ES2040847T3 true ES2040847T3 (es) 1996-07-16

Family

ID=27263407

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88303560T Expired - Lifetime ES2040847T3 (es) 1987-04-27 1988-04-20 Un procedimiento para preparar una composicion farmaceutica que contiene una sal de litio.

Country Status (11)

Country Link
EP (1) EP0289204B1 (es)
JP (1) JP2699083B2 (es)
AU (1) AU618730B2 (es)
CA (1) CA1306944C (es)
DE (1) DE3863678D1 (es)
DK (1) DK173068B1 (es)
ES (1) ES2040847T3 (es)
GR (1) GR3002426T3 (es)
HK (1) HK127793A (es)
IE (1) IE60568B1 (es)
NZ (1) NZ224380A (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01135704A (ja) * 1987-11-18 1989-05-29 Medical Res Internatl Ltd 微生物を破壊する表面処理方法
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
FI912955L (fi) * 1990-06-25 1991-12-26 Res Found Mental Hygiene Antimikroba fettsyrasammansaettningar.
GB9023701D0 (en) * 1990-10-31 1990-12-12 Efamol Holdings Medical treatment
EP0585057A1 (en) * 1992-08-25 1994-03-02 Scotia Holdings Plc Lithium salts of fatty acids for the treatment of viral infections and cancer
GB9218064D0 (en) * 1992-08-25 1992-10-14 Efamol Holdings Method for the safe intravenous administration of fatty acids
GB9301446D0 (en) * 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
GB9304746D0 (en) * 1993-03-09 1993-04-28 Scotia Holdings Plc Treatment of viral infections
AU1067795A (en) * 1993-11-26 1995-06-13 Karla Lehmann Use of lithium compounds in the treatment and prevention of alzheimer's disease
GB2300807B (en) * 1995-05-15 1999-08-18 Tillotts Pharma Ag Oral dosage forms of omega-3 polynunsaturated acids for the treatment of inflammatory bowel disease
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
WO1997039759A2 (en) * 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
DE19629433A1 (de) * 1996-07-22 1998-01-29 Hoechst Ag Omega-3-fettsäurenenthaltende Zubereitung aus Mikroorganismen als Prophylaktikum bzw. Therapeutikum gegen parasitäre Erkrankungen beim Tier
GB9621990D0 (en) * 1996-10-22 1996-12-18 Scotia Pharma Ltd Use
US6344482B1 (en) 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
US6852870B2 (en) 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
CA2308489A1 (en) 1997-10-09 1999-04-22 Emory University Method and devices for transdermal delivery of lithium
GB9904895D0 (en) * 1999-03-03 1999-04-28 Scarista Limited Regulators of coenzyme-A-independent transacylase as psychotropic drugs
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0425658D0 (en) * 2004-11-22 2004-12-22 Stanford Rook Ltd Immunotherapeutic agent
GB201001345D0 (en) * 2010-01-27 2010-03-17 Equateq Ltd Process for preparing and purifying fatty acids
BRPI1000970A2 (pt) * 2010-04-07 2011-11-29 Fundacao Arnaldo Vieira De Carvalho composição farmacêutica para o tratamento da doença de alzheimer, processo para sua obtenção e uso
CN107050457A (zh) 2012-01-06 2017-08-18 翁特拉制药公司 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
EP2846779A4 (en) 2012-05-07 2015-12-16 Omthera Pharmaceuticals Inc STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639625A (en) * 1967-07-13 1972-02-01 Lewis Sherwin Compositions containing lithium succinate
US4172123A (en) * 1968-07-19 1979-10-23 Grillo-Werke Aktiengesellschaft Deodorants for both cosmetic and commercial use
FR2125219A1 (en) * 1971-02-19 1972-09-29 Greene Martin Lithium undecylenate for topical fungal disorders
FR2244485A1 (en) * 1973-08-06 1975-04-18 Aries Robert Lithium dicarboxylic acid salts - in compositions for treatment of psychoses, esp. manic depression
US4328243A (en) * 1981-04-07 1982-05-04 Horrobin David F Manic-depressive illnesses
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
US4398937A (en) * 1981-10-06 1983-08-16 The University Of Southern Mississippi Selective algaecides for control of cyanochloronta
AU556817B2 (en) * 1982-02-03 1986-11-20 Efamol Limited Topical application of a lithium salt and dihomo-alpha- linolenic acid
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
US4582709A (en) * 1985-02-08 1986-04-15 Warner-Lambert Company Chewable mineral supplement
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
AU6768587A (en) * 1987-01-19 1988-07-21 Donnini, Tatiana Ceramic tile cutter

Also Published As

Publication number Publication date
DE3863678D1 (de) 1991-08-22
EP0289204B1 (en) 1991-07-17
DK225588D0 (da) 1988-04-26
IE881244L (en) 1988-10-27
IE60568B1 (en) 1994-07-27
DK225588A (da) 1988-10-28
AU618730B2 (en) 1992-01-09
NZ224380A (en) 1991-06-25
AU1536188A (en) 1988-10-27
EP0289204A3 (en) 1989-04-26
JPS6413021A (en) 1989-01-17
CA1306944C (en) 1992-09-01
EP0289204A2 (en) 1988-11-02
DK173068B1 (da) 1999-12-13
JP2699083B2 (ja) 1998-01-19
GR3002426T3 (en) 1992-12-30
HK127793A (en) 1993-11-26

Similar Documents

Publication Publication Date Title
ES467828A1 (es) Un procedimiento para preparar nuevos compuestos de cefem y cefam
PT95343A (pt) Processo para a preparacao de composicoes farmaceuticas contendo doses baixas de um agente anticoagulante oral tal como o warfarin e de um inibidor de plaquetas tal como o acido acetilsalilico,como ingredientes acticovos apropriadas para otratamento e/ou prevencao de doencas cardiacas
ES2052914T3 (es) Un procedimiento para preparar un complejo de beta-dextrina con una sal de ibuprofeno.
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
DE69019084D1 (de) Methoden zur Verhinderung von Schimmel.
ES2129485T3 (es) Derivados de acidos guanidinoalquil-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
ES2041971T3 (es) Composiciones orales.
ES2008865B3 (es) Procedimiento para preparar una composicion antiseptica.
ATE135208T1 (de) Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen
ES2061650T3 (es) Composiciones para el tratamiento de la enfermedad periodontal.
ECSP941082A (es) Procedimiento para la preparacion de la sal sodica cristalina adhidra de 5- cloro-3 (2-tenoli)-2- oxindol-1 carboxamida
RO92199A (ro) Compozitie pentru sterilizarea anterelor masculine ale plantelor
DE3662041D1 (en) New carboxylic acid derivatives, their manufacturing process, use and medicines containing these compounds
ES2002398A6 (es) Procedimiento para preparar nuevas enolamidas
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
MX9701514A (es) Limpieza, desinfeccion y preparacion de lentes de contacto.
AR240974A1 (es) Composiciones para lucha contra malezas herbaceas en cultivos de plantas utiles
ES2053856T3 (es) Derivados del acido 4-quinoleino carboxilico utiles para el tratamiento de enfermedades de la piel y del muco-epitelio.
ES507810A0 (es) Procedimiento para hidroformilar compuestos olefinicamente insaturados.
ES2038289T3 (es) Utilizacion de 15-ceto-pges para la fabricacion de un medicamento para aumentar la temperatura corporal.
DK137589A (da) Salicylsyreholdigt middel til behandling af hudsygdomme
ES2038216T3 (es) Procedimiento para la preparacion de 5-(3-alquil-5-t-butil-4-hidroxi-fenil)-2-amino-6h-1,3,4-tiadazinas y su empleo.
BR8702354A (pt) Composicao bactericida e processo para controlar doencas bacteriacas em plantas
AR004496A1 (es) Compuestos para combatir parasitos, agente que los contiene, empleo de dichos compuestos para combatir parasitos, procedimiento para combatir yprevenir los parasitos, simiente tratada y productos intermediarios para su exclusivo uso en el procedimiento de preparacion de dichos compuestos.
MX173156B (es) Composiciones para tratar o evitar la placa dental o enfermedades gingivales o periodontales de la cavidad oral en humanos o animales inferiores

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 289204

Country of ref document: ES

FG2A Definitive protection

Ref document number: 0289204

Country of ref document: ES